Dexlansoprazole
- Generic Name
- Dexlansoprazole
- Brand Names
- Dexilant
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N3O2S
- CAS Number
- 138530-94-6
- Unique Ingredient Identifier
- UYE4T5I70X
- Background
Dexlansoprazole is a new generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of Lansoprazole, which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes Pa...
- Indication
Dexlansoprazole is a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for:
- Associated Conditions
- Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Healed erosive esophagitis
- Associated Therapies
- -
Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 296
- Registration Number
- NCT02351960
Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation
- Conditions
- Interventions
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 6
- Registration Number
- NCT02162758
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 8
- Registration Number
- NCT02096458
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 104
- Registration Number
- NCT01642602
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
- Conditions
- Interventions
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 63
- Registration Number
- NCT01642615
Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain
- Conditions
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- University of Iowa
- Registration Number
- NCT01637571
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2011-11-24
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT01479231
Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy
- Conditions
- Interventions
- First Posted Date
- 2011-04-05
- Last Posted Date
- 2011-04-05
- Lead Sponsor
- Advanced Center for Specialty Care
- Target Recruit Count
- 80
- Registration Number
- NCT01328652
- Locations
- 🇺🇸
Advanced Center for Specialty Care, Chicago, Illinois, United States
Evaluating Treatment Response in Laryngo-Pharyngeal Reflux
- Conditions
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- University of Washington
- Registration Number
- NCT01328392
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux
- Conditions
- Interventions
- First Posted Date
- 2011-03-17
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 11
- Registration Number
- NCT01317472
- Locations
- 🇺🇸
Clarian North Hospital -- IUMG Clinic, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.